Annual LNP Formulation and Process Development Summit on April 14-16, 2025 in Boston, United States

With Arbor Biotechnologies on-track for year-end IND/CTA filing of their LNP-mediated gene editing therapy and LNPs continuing to be the hottest delivery vehicle across all payload types, completely dominating the non-viral delivery field, the promise of this delivery vehicle is truly exciting!

The 4th LNP Formulation and Process Development Summit returns to Boston, as the only industry summit dedicated to showcasing the hottest pre-clinical and clinical data, overcoming the greatest challenges within the LNP IP space and uncovering the most innovative LNP formulations for cell-specific delivery outside the liver.

With a revamped track design, the 2025 meeting has 3 dedicated streams, Analytical Development and Characterization, Formulation and Delivery and Process Development and Manufacturing to deep dive into an end-to-end strategy for revolutionizing the development of potent, safe and stable LNPs for a variety of payloads.

Uniting 300+ LNP trailblazers from across the globe, this is your one-stop-shop for LNP specific networking, partnership opportunities and collaborative discussions to further fuel advancement of LNPs towards clinical development and beyond.

URLs:

Tickets: https://go.evvnt.com/2734593-2?pid=10008

Brochure: https://go.evvnt.com/2734593-3?pid=10008

Time: 8:00 AM - 5:00 PM

Prices:

Drug Developer Pricing - Conference Only: USD 3199.00,

Drug Developer Pricing - Conference + 1 Workshop: USD 3798.00,

Drug Developer Pricing - Conference + LNP 101 Day: USD 4397.00,

Solution Provider - Conference + LNP 101 Day: USD 5297.00,

Solution Provider - Conference + 1 Workshop: USD 4598.00,

Solution Provider - Conference Only: USD 3899.00,

Academic Pricing - Conference Only: USD 2799.00,

Academic Pricing - Conference + 1 Workshop: USD 3298.00,

Academic Pricing - Conference + LNP 101 Day: USD 3797.00

Speakers: Annette Bak Head, Advanced Drug Delivery, AstraZeneca, Magali Hickey Head, LNP Process Development, Moderna, Pieter Cullis Professor, University of British Columbia, Sanyogitta Puri Senior Director, Non- Viral Delivery, Novo Nordisk, Anni Chang Senior Scientist II, Excipients GSSD, US Pharmacopeia, Bo Ying Chief Executive Officer , Abogen Biosciences, Daniel Shores Daniel Shores Partner, Rothwell Figg, David Chu Senior Director, Analytical Operations, Capstan Therapeutics, Jee-Young Park Executive Director, MediciBIO, Jie Su Head, Formulation, Zipcode Bio, Jivan Yewle Director, Non-Viral Delivery, Mammoth Biosciences, Kanika Suri Scientist, Takeda Pharmaceuticals, Katherine Cook Scientist II , Tessera Therapeutics, Melissa Hanson Senior Principal Scientist, Bristol Myers Squibb, Muthiah (Mano) Manoharan Senior Vice President, Innovation Chemistry and Alnylam Distinguished Scientist Alnylam Pharmaceuticals, Peng Zhang Principal Scientist, US Pharmacopeia, Saswata Karmakar Director, Chemistry, Sanofi, Shengshuang Zhu Senior Principal Scientist, Arbor Biotechnologies, Srinivasulu Bandi Director, External Manufacturing, Sail Biomedicines, Zi Jun Emma Wang Chief Technology Officer Yoltech Therapeutics, Alexey Popov Vice President, Head, Process Development, Sail Biomedicines, Alireza Nomani Principal Scientist, Regeneron Pharmaceuticals, Ami Jo Associate Director, Process Development, Omega Therapeutics, Amit Singh Director, Delivery Discovery , RNA NewCo, Anubhav Arora Director, Chemistry , Manufacturing and Controls Apellis Pharmaceuticals, Benjamin Frempah Director, Business Development , Omega Therapeutics, Bindu Varghese Executive Director, Research ,Carisma Therapeutics, Ching Kim Tye Head, LNP Platform Development , Sanofi, Erika Jensen Principal Scientist , Pfizer, Felipe Gazos Lopes Associate Director, Analytical Development , Tessera Therapeutics, George Dakwar Director, Formulation Platform, Tessera Therapeutics, Hui Li Research and Development Director, Innorna, Jieni Xu Head, Delivery Science , Editas Medicine, John Lewis Chief Executive Officer , Entos Pharmaceuticals, Luis Santos Senior Director , Prime Medicine, Mandana Borna Head, Oligonucleotide Drug Product Development, Biogen, Mansoor Amiji University Distinguished Professor, Northeastern University, Pintu Kanjilal Scientist, LNP Discovery, Strand Therapeutics, Qook Lee Research Advisor, Eli Lilly and Co, Rajesh Krishnan Senior Director, Formulation, Providence Therapeutics, Rui Zhang Director, Stylus Medicine, Rumpa Bhattacharjee Senior Scientist II, ReCode Therapeutics, Sashini Wijetunge Senior Scientist , Pfizer, Sudhakar Garad Global Head, Pre-formulation, Novel Delivery and Biopharmaceutics , Novartis, Sujit Jain Senior Director, Chemistry, Manufacturing and Controls Operations, SalioGen Therapeutics, Swathi Pullagurla Senior Scientist , Gritstone Bio, Thomas Cleveland Physicist , NIST, Yan Xia Head, Nanotechnology Formulations, Axelyx, Zhengrong Cui Professor, The University of Texas at Austin